In vitro Predictive Toxicity Testing

The Bioluminomics principle assay products for high throughput in vitro toxicity screening during early and late stage drug development.

The assays are designed for:

  • Basic research toxicology and pharmacology
  • Toxicology, risk and safety assessment for biopharmaceutical companies
  • Environmental testing

Preferred Cell Systems provides assays for in vitro toxicity screening. The testing principle is based on the determination of the intracellular ATP concentration by measuring the correlated bioluminescence on 96-well plates. For validation the assay kits include standard & controls.

The Bioluminomics principle:

Principle Bioluminescence
The Halo Principle
Cell Type Assay Name Assay Type Application
HEMATOPOIETIC
STEM CELLS
HALO®-Tox HT Suspension Expansion Culture High throughput hemotoxicity screening
HALO® PRT Residual hemotoxicity and drug sensitivity change
MESENCHYMAL STROMA CELLS MSCGlo-Tox HT Adherent cell expansion High throughput MSC cytotoxicity screening
IMMUNE CELLS ImmunoGlo-Tox HT Adherence or non-adherence growth-expansion High throughput toxicity screening
PRIMARY STEM CELLS AND CELL LINES STEMGlo-Tox HT High throughput stem cell toxicity screening
STEMGlo-PRT Residual stem cell toxicity and drug sensitivity change
HEPATOCYTES HepatoGlo-Tox HT High throughput hepatotoxicity screening

Readout: ATP bioluminescence (96- or 384-well plates)
Kit components: Master mix, ATP standard, ATP controls, 96-well plate(s), sterile adhesive foil, manual

HALO® PRT measuring:


Results measuring predictive residual toxicity with HALO-96 PRT assays

source: www.hemogenix.com